Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
第一作者:
Jaejin,An
第一单位:
Kaiser Permanente Southern California, Pasadena, California; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California. Electronic address: jaejin.x.an@kp.org.
作者:
医学主题词
成年人(Adult);人类(Humans);心房颤动(Atrial Fibrillation);抗凝药(Anticoagulants);肌酸酐(Creatinine);治疗结果(Treatment Outcome);出血(Hemorrhage);卒中(Stroke);栓塞(Embolism);吡啶酮类(Pyridones);投药, 口服(Administration, Oral)
DOI
10.1016/j.clinthera.2023.05.007
PMID
37380555
发布时间
2023-08-29
- 浏览0
Clinical therapeutics
e151-e158页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



